Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service structural heart (TAVR, TEER) cases in Vermont: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (219 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 154 | 13% |
| 2020 | 5 | 168 | 16% |
| 2021 | 5 | 162 | 22% |
| 2022 | 5 | 170 | 30% |
| 2023 | 5 | 166 | 33% |
| 2024 | 6 | 189 | 35% |
| 2025 from claims | – | 180 146–212 | 34% |
| 2026 forecast | – | 227 178–285 | 14% |
| 2027 forecast | – | 243 180–321 | 10% |
| 2028 forecast | – | 260 184–359 | 7% |
| 2029 forecast | – | 278 189–398 | 4% |
| 2030 forecast | – | 296 194–440 | 1% |
Transcatheter aortic valve replacement and mitral edge-to-edge repair. Professional codes (what the surgeon bills): CPT 33361, 33362, 33363, 33364, 33365, 33366, 33418, 33419; the hospital bills MS-DRG 266, 267.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Vermont; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 150 | 4,552+1.5%/yr | +1.5%/yr | 2.1 | 0% | 6,000 in 2030+4.7%/yr |
| Pennsylvania | 158 | 2,820+2.5%/yr | +2.5%/yr | 1.7 | 0% | 3,580 in 2030+4%/yr |
| Massachusetts | 66 | 2,037+3.4%/yr | +3.4%/yr | 1.9 | 0% | 3,210 in 2030+7.9%/yr |
| New Jersey | 71 | 1,653+2.7%/yr | +2.7%/yr | 1.4 | 0% | 2,140 in 2030+4.4%/yr |
| New Hampshire | 24 | 582+6.7%/yr | +6.7%/yr | 2.3 | 0% | 1,340 in 2030+15%/yr |
| Connecticut | 32 | 563−1.1%/yr | −1.1%/yr | 1.4 | 0% | 1,000 in 2030+10%/yr |
| Rhode Island | 9 | 263+10%/yr | +10%/yr | 2.3 | 0% | 340 in 2030+4.3%/yr |
| Maine | 15 | 221+2.2%/yr | +2.2%/yr | 1.1 | 0% | 460 in 2030+13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 8 | 437−6.6%/yr | −6.6%/yr | 3.40.7× | 0% | 790 in 2030+10%/yr |
Structural heart (TAVR, TEER) in every state, and its device makers · Every procedure market in Vermont · Every state · Compare with New York
Medtronic leads with 70% of company spending on these surgeons in 2025, −8 pts on 2024.
In 2025, 3 companies reported engagement with Vermont’s surgeons worth $124K in consulting, speaking, meals and travel tied to these products, about $21K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 52 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.